These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 17252625)
1. Focus on hepatitis. HCV protease inhibitor does well in early clinical trial. Carter M IAPAC Mon; 2006 Feb; 12(2):50-1. PubMed ID: 17252625 [No Abstract] [Full Text] [Related]
2. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
3. Excitement grows for potential revolution in hepatitis C virus treatment. Opar A Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732 [No Abstract] [Full Text] [Related]
4. A promising new anti-HCV protease inhibitor. Sulkowski M Hopkins HIV Rep; 2003 Jan; 15(1):7. PubMed ID: 12542005 [No Abstract] [Full Text] [Related]
6. [Progression of treatment of hepatitis C--peginterferon]. Pawłowska M; Halota W Przegl Epidemiol; 2001; 55 Suppl 3():169-73. PubMed ID: 11984947 [No Abstract] [Full Text] [Related]
7. Focus on hepatitis. Weight-based versus fixed-dose peginterferons. Shaw-Stiffel T IAPAC Mon; 2004 May; 10(5):178-80. PubMed ID: 15366103 [No Abstract] [Full Text] [Related]
8. Hepatitis C virus therapies. Smith RE Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802 [No Abstract] [Full Text] [Related]
9. Treatment of hepatitis C 2010: a focus on protease inhibitors. Lemon M S D Med; 2010 Jun; 63(6):214-5. PubMed ID: 20853592 [No Abstract] [Full Text] [Related]
10. Phase 1 trial starts for HCV protease inhibitor. AIDS Patient Care STDS; 2009 Mar; 23(3):225. PubMed ID: 19866544 [No Abstract] [Full Text] [Related]
11. [Treatment of hepatitis C: current status and perspectives]. Pol S; Corouge M Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038 [TBL] [Abstract][Full Text] [Related]
12. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Childs-Kean LM; Hand EO Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Thomson JA; Perni RB Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221 [TBL] [Abstract][Full Text] [Related]
15. [PEG-interferon alfa 2a against hepatitis C. Better as the standard therapy]. MMW Fortschr Med; 2001 Nov; 143(44):58. PubMed ID: 11732405 [No Abstract] [Full Text] [Related]
16. Worth the wait. New, more effective therapies for hepatitis C are on the way. Learned J Posit Aware; 2011; 23(1):15-8. PubMed ID: 21314021 [No Abstract] [Full Text] [Related]
20. [Progress in Examination and Treatment of Hepatitis C Virus]. Suda G; Sakamoto N Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]